Teleflex Incorporated announced the sale of its OEM, Acute Care and Interventional Urology businesses to private‑equity firms Montagu and Kohlberg and Intersurgical Ltd. for a total of $2.03 billion in cash. The OEM unit, which supplies custom‑engineered interventional catheter components, will become an independent contract developer and manufacturer after closing in the second half of 2026. The Acute Care and Interventional Urology units, which together represented roughly 11 % of Teleflex’s 2024 revenue, will be integrated into Intersurgical’s existing operations.
The transaction is expected to generate about $1.8 billion in net proceeds after tax. Teleflex’s Board has authorized a new $1 billion share‑repurchase program that will be funded primarily by the sale proceeds, and the company plans to use the remaining cash to reduce debt. The sale therefore provides a significant liquidity boost and a clear path to improving the company’s capital structure.
The divestiture is part of Teleflex’s long‑term strategy to focus on its high‑growth vascular access, interventional and surgical markets. Earlier in 2025 the company had announced a plan to spin off the OEM, Acute Care and Urology units into a separate public company, but the sale to private equity represents a faster route to unlocking value. Management cited declining sales of the UroLift device in the urology unit and the loss of a key OEM customer as headwinds that made the sale an attractive option. By shedding these legacy businesses, Teleflex can concentrate resources on its core segments, which accounted for 24 % (vascular access), 19 % (interventional) and 15 % (surgical) of 2024 revenue.
CEO Liam Kelly said the transaction “confirms Teleflex’s commitment to becoming a more focused medical‑technology leader.” He added that the buyers are well positioned to invest in the divested units and that the sale will free capital for the company to pursue growth opportunities in its core markets. The announcement also signals confidence in the company’s ability to generate cash and reduce leverage while maintaining a strong balance sheet.
The market reacted positively to the announcement. Analysts noted that the sale delivers a large cash influx, a robust share‑repurchase program, and a clearer strategic focus, all of which are viewed as positive catalysts for Teleflex’s future performance.
The divestiture positions Teleflex to accelerate growth in its core high‑margin segments, improve its debt profile, and create a more streamlined organization that can pursue additional acquisitions or organic expansion in vascular access and interventional markets. The sale also provides a platform for Teleflex to potentially revisit a spin‑off or other capital‑raising strategies once the legacy units are fully integrated and the company’s financial position is strengthened.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.